收藏切换
Dutastreride in the treatment of benign prostatic hyperplasia: a rapid health technology assessment
收藏切换
Yue LIU1, Min ZHAO2, Rui-fang SUN1, Suo-di ZHAI3
Chinese Journal of New Drugs | 2021, 30(15) : 1435 - 1440
Less
收藏切换
Chinese Journal of New Drugs | 2021, 30(15): 1435-1440
Dutastreride in the treatment of benign prostatic hyperplasia: a rapid health technology assessment
Full
Yue LIU1, Min ZHAO2, Rui-fang SUN1, Suo-di ZHAI3
Affiliations
  • 1Department of Pharmacy, Civil Aviation General Hospital, Beijing 100025, China
  • 2Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
  • 3Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China
Published: 2021-08-15
Outline
收藏切换
Objective:

To evaluate the efficacy, safety and pharmacoeconomics of dutastreride in the treatment of benign prostatic hyperplasia to meet the demand of decision-making.

Methods:

CNKI, Wanfang, Pubmed, the Cochrane Library and CRD databases were systematically searched. Studies were selected according to the inclusion and exclusion criteria, and the data were extracted. The quality of included literature was separately evaluated and analyzed by 2 reviewers.

Results:

Finally, 10 systematic reviews and 11 pharmacoeconomic studies were included. The results suggested that dutasteride alone or combined with tamsulosin can effectively improve International Prostate Symptom Score, increase maximum urine flow, delay the growth of prostate volume, and reduce acute urinary retention and prostate-related surgery. The incidence of sexual adverse events is higher, including decreased libido, erectile dysfunction, abnormal ejaculation and so on. Compared with finasteride, there was no significant difference in efficacy and safety. Foreign studies showed that the combination therapy of dutasteride and tamsulosin had economic advantages compared with tamsulosin alone, while domestic economic research results were inconsistent.

Conclusion:

As a drug treating benign prostatic hyperplasia, dutasteride has good efficacy and safety; however, it has no advantages over finasteride, and the reliable conclusion needs the support of more head-to-head direct tests of dutasteride and finasteride.

dutastreride  /  benign prostatic hyperplasia  /  efficacy  /  safety  /  economic
刘玥, 赵敏, 孙瑞芳, 翟所迪. 度他雄胺治疗良性前列腺增生的快速卫生技术评估. 中国新药杂志, 2021 , 30 (15) : 1435 -1440 .
Yue LIU, Min ZHAO, Rui-fang SUN, Suo-di ZHAI. Dutastreride in the treatment of benign prostatic hyperplasia: a rapid health technology assessment[J]. Chinese Journal of New Drugs, 2021 , 30 (15) : 1435 -1440 .
Year 2021 volume 30 Issue 15
43
8
Cite this Article
BibTeX
Article Info
  • Online Date:2026-10-28
  • Published:2021-08-15
Article Data
Affiliations
History
  • Accepted:2020-12-10
Affiliations
    1Department of Pharmacy, Civil Aviation General Hospital, Beijing 100025, China
    2Department of Pharmacy, The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, China
    3Institute for Drug Evaluation, Peking University Health Science Center, Beijing 100191, China
References
Share
https://castjournals.cast.org.cn/joweb/zgxyzz/EN/
Share to
QR

Scan QR to access full text

Cite this article
BibTeX
Citations
表12种不同金属材料的力学参数
科
Family
属数
Number of
genus
种数
Number of
species
占总种数比例
Percentage of
total species (%)
属
Genus
种数
Number of
species
占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
  • BibTeX
  • EndNote
  • RefWorks
  • TxT